Skip Nav Destination
Issues
1 November 2017
-
Cover Image
Cover Image
ABOUT THE COVER
The extracellular matrix limits the efficacy of chemotherapy in pancreatic ductal adenocarcinoma (PDA) in part by active cell signaling. Discoidin domain receptor 1 (DDR1) is a receptor tyrosine kinase that binds fibrillar collagens and is expressed by PDA tumor cells. The image shows phosphorylated DDR1 staining in human PDA highlighting active collagen signaling in PDA tumor cells. Aguilera and colleagues demonstrate that pharmacologic inhibition of DDR1 with the small molecule 7rh substantially improves the efficacy of standard chemotherapy in robust preclinical models of PDA in the absence of additional normal tissue toxicity. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1535-7163
EISSN 1538-8514
Highlights
Small Molecule Therapeutics
Author Choice
Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)
Ursula A. Germann; Brinley F. Furey; William Markland; Russell R. Hoover; Alex M. Aronov; Jeffrey J. Roix; Michael Hale; Diane M. Boucher; David A. Sorrell; Gabriel Martinez-Botella; Matthew Fitzgibbon; Paul Shapiro; Michael J. Wick; Ramin Samadani; Kathryn Meshaw; Anna Groover; Gary DeCrescenzo; Mark Namchuk; Caroline M. Emery; Saurabh Saha; Dean J. Welsch
The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma
Ronan Le Moigne; Blake T. Aftab; Stevan Djakovic; Eugen Dhimolea; Eduardo Valle; Megan Murnane; Emily M. King; Ferdie Soriano; Mary-Kamala Menon; Zhi Yong Wu; Stephen T. Wong; Grace J. Lee; Bing Yao; Arun P. Wiita; Christine Lam; Julie Rice; Jinhai Wang; Marta Chesi; P. Leif Bergsagel; Marianne Kraus; Christoph Driessen; Szerenke Kiss Von Soly; F. Michael Yakes; David Wustrow; Laura Shawver; Han-Jie Zhou; Thomas G. Martin, III; Jeffrey L. Wolf; Constantine S. Mitsiades; Daniel J. Anderson; Mark Rolfe
Combination Therapy with c-Met and Src Inhibitors Induces Caspase-Dependent Apoptosis of Merlin-Deficient Schwann Cells and Suppresses Growth of Schwannoma Cells
Marisa A. Fuse; Stephani Klingeman Plati; Sarah S. Burns; Christine T. Dinh; Olena Bracho; Denise Yan; Rahul Mittal; Rulong Shen; Julia N. Soulakova; Alicja J. Copik; Xue Zhong Liu; Fred F. Telischi; Long-Sheng Chang; Maria Clara Franco; Cristina Fernandez-Valle
Targeting TAO Kinases Using a New Inhibitor Compound Delays Mitosis and Induces Mitotic Cell Death in Centrosome Amplified Breast Cancer Cells
Chuay-Yeng Koo; Caterina Giacomini; Marta Reyes-Corral; Yolanda Olmos; Ignatius A. Tavares; Charles M. Marson; Spiros Linardopoulos; Andrew N. Tutt; Jonathan D.H. Morris
mTOR Kinase Inhibition Effectively Decreases Progression of a Subset of Neuroendocrine Tumors that Progress on Rapalog Therapy and Delays Cardiac Impairment
Melissa A. Orr-Asman; Zhengtao Chu; Min Jiang; Mariah Worley; Kathleen LaSance; Sheryl E. Koch; Vinicius S. Carreira; Hanan M. Dahche; David R. Plas; Kakajan Komurov; Xiaoyang Qi; Carol A. Mercer; Lowell B. Anthony; Jack Rubinstein; Hala E. Thomas
Large Molecule Therapeutics
Wilms Tumor NCAM-Expressing Cancer Stem Cells as Potential Therapeutic Target for Polymeric Nanomedicine
Ela Markovsky; Einav Vax; Dikla Ben-Shushan; Anat Eldar-Boock; Rachel Shukrun; Eilam Yeini; Iris Barshack; Revital Caspi; Orit Harari-Steinberg; Naomi Pode-Shakked; Benjamin Dekel; Ronit Satchi-Fainaro
Cancer Biology and Translational Studies
Inhibition of Discoidin Domain Receptor 1 Reduces Collagen-mediated Tumorigenicity in Pancreatic Ductal Adenocarcinoma
Kristina Y. Aguilera; Huocong Huang; Wenting Du; Moriah M. Hagopian; Zhen Wang; Stefan Hinz; Tae Hyun Hwang; Huamin Wang; Jason B. Fleming; Diego H. Castrillon; Xiaomei Ren; Ke Ding; Rolf A. Brekken
Author Choice
The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2Hi Macrophages in Breast Cancer and Pancreatic Neuroendocrine Tumors
Allison S. Harney; George S. Karagiannis; Jeanine Pignatelli; Bryan D. Smith; Ece Kadioglu; Scott C. Wise; Molly M. Hood; Michael D. Kaufman; Cynthia B. Leary; Wei-Ping Lu; Gada Al-Ani; Xiaoming Chen; David Entenberg; Maja H. Oktay; Yarong Wang; Lawrence Chun; Michele De Palma; Joan G. Jones; Daniel L. Flynn; John S. Condeelis
PPARγ Ligand–induced Annexin A1 Expression Determines Chemotherapy Response via Deubiquitination of Death Domain Kinase RIP in Triple-negative Breast Cancers
Luxi Chen; Yi Yuan; Shreya Kar; Madhu M. Kanchi; Suruchi Arora; Ji E. Kim; Pei F. Koh; Einas Yousef; Ramar P. Samy; Muthu K. Shanmugam; Tuan Z. Tan; Sung W. Shin; Frank Arfuso; Han M. Shen; Henry Yang; Boon C. Goh; Joo I. Park; Louis Gaboury; Peter E. Lobie; Gautam Sethi; Lina H.K. Lim; Alan P. Kumar
Synthetic Lethality Interaction Between Aurora Kinases and CHEK1 Inhibitors in Ovarian Cancer
Ana Alcaraz-Sanabria; Cristina Nieto-Jiménez; Verónica Corrales-Sánchez; Leticia Serrano-Oviedo; Fernando Andrés-Pretel; Juan Carlos Montero; Miguel Burgos; Juan Llopis; Eva María Galán-Moya; Atanasio Pandiella; Alberto Ocaña
T790M-Selective EGFR-TKI Combined with Dasatinib as an Optimal Strategy for Overcoming EGFR-TKI Resistance in T790M-Positive Non–Small Cell Lung Cancer
Satomi Watanabe; Takeshi Yoshida; Hisato Kawakami; Naoki Takegawa; Junko Tanizaki; Hidetoshi Hayashi; Masayuki Takeda; Kimio Yonesaka; Junji Tsurutani; Kazuhiko Nakagawa
Author Choice
EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL
Dorothy Brach; Danielle Johnston-Blackwell; Allison Drew; Trupti Lingaraj; Vinny Motwani; Natalie M. Warholic; Igor Feldman; Christopher Plescia; Jesse J. Smith; Robert A. Copeland; Heike Keilhack; Elayne Chan-Penebre; Sarah K. Knutson; Scott A. Ribich; Alejandra Raimondi; Michael J. Thomenius
Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers
Models and Technologies
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.